CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273181608
- Phone
- 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-14 | KIRSKE DAVID Chief Financial Officer | Grant or award · Stock Option (right to buy) | +352,800 | 352,800 | ||
| 2025-08-12 | Volpone John President | Grant or award · Stock Option (right to buy) | +1,609,873 | 1,609,873 | ||
| 2025-08-12 | Craig Adam R Executive Chairman | Grant or award · Stock Option (right to buy) | +1,609,873 | 1,609,873 | ||
| 2025-08-12 | KIRSKE DAVID Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,073,249 | 1,073,249 | ||
| 2025-06-09 | Stewart Murray Director | Grant or award | +1,500 | 7,883 | ||
| 2025-06-09 | de Craecker Francoise Director | Grant or award | +1,500 | 4,722 | ||
| 2025-06-09 | Bridger Gary Director | Grant or award | +1,500 | 4,722 | ||
| 2025-06-09 | Woods Keith Director | Grant or award | +1,500 | 6,000 | ||
| 2025-06-09 | MCGIRR DAVID W J Director | Grant or award | +1,500 | 4,722 | ||
| 2025-06-09 | WYZGA MICHAEL S Director | Grant or award | +1,500 | 5,555 | ||
| 2025-05-20 | Thoren Natasha Fay Chief Legal Officer | Grant or award | +3,333 | 9,462 | ||
| 2025-05-16 | Baldry Mark Chief Commercial Officer | Grant or award | +1,032 | $2.48 | $3K | 25,337 |
| 2025-05-16 | Baldry Mark Chief Commercial Officer | Purchase | +1,032 | $2.48 | $3K | 25,337 |
| 2025-02-12 | Arbet-Engels Christophe Chief Medical Officer | Grant or award | +850,000 | 864,207 | ||
| 2025-02-12 | Mostafa Adam S. Chief Financial Officer | Grant or award | +850,000 | 850,000 | ||
| 2025-02-12 | Ragan Paula President and CEO | Grant or award | +2,250,000 | 3,337,386 | ||
| 2025-02-12 | Baldry Mark Chief Commercial Officer | Grant or award | +600,000 | 729,173 | ||
| 2025-02-12 | DiBiase Mary Chief Operating Officer | Grant or award | +650,000 | 1,140,980 | ||
| 2025-01-24 | Ragan Paula President and CEO | Sale | −76,473 | $0.45 | $35K | 1,087,386 |
| 2025-01-24 | Mostafa Adam S. Chief Financial Officer | Sale | −74,773 | $0.45 | $34K | 0 |
Page 2 of 6 · 120 trades